Jiangxi LongLife Bio-pharmaceutical Co., Ltd. was founded by Dr. James Wu in 2009. As a subsidiary of Chiral Quest(Suzhou) Co., Ltd., Longlife is dedicated to the development and industrialization of innovative drugs and high-end generic drugs.

Located in Jinxian Industrial Park, Jiangxi province, LongLife covers an area of 166,650 square meters in total with the plant construction area, more than 13,000 square meters. The company has invested more than 23 million dollars to establish a new plant which accords with the standard of cGMP. In year 2018, LongLife passed US FDA audit.

LongLife has serials of products involve in anti-cancer, anti-diabetic,anti-HIV and anti-depressant. Our main products including the intermediates of Duloxetine, Sitagliptin,  Sacubitril, Dolutegravir, Ibrutinib, Upadacitinib, etc. We innovate the manufacturing route of Duloxetine, cut down the cost of raw material and manufacturing, meanwhile keep the high level of quality.

In year 2020, with the merge with Suzhou Pengxu Pharmatech Co., Ltd., both Longlife (manufacturing site) and Pengxu (R&D site) become the wholly owned subsidiary of Chiral Quest (Suzhou) Co., Ltd. With the advantage of advanced technology, experienced management team and high-quality talents, Jiangxi Longlife will develop into a first-class and highly competitive international pharmaceutical enterprise.